

Altered Total Antioxidant Capacity and Malondialdehyde in Cervical Cancer Patients and Effect of Chemoradiation

Shah SR¹, Shaheen B Shaikh¹, Shaheena Yassir^{1*}¹Department of Biochemistry, Yenepoya Medical College, Yenepoya (Deemed to be) University, Mangalore Karnataka, IndiaDOI: [10.36348/sijb.2021.v04i2.001](https://doi.org/10.36348/sijb.2021.v04i2.001)

| Received: 21.02.2021 | Accepted: 03.03.2021 | Published: 08.03.2021

*Corresponding author: Shaheena Yassir

Abstract

Background: One of the leading causes of cancer-related death in women worldwide, that causes an enhanced negative impact on quality of life with regard to social and economic burden, is Cervical cancer (CaCx). Early diagnosis and treatment can plummet associated mortality and morbidity, by hit hard and early approach. **Aim and objective:** To estimate serum total antioxidant capacity (TAC), and malondialdehyde (MDA) in CaCx patients and analyse their response to chemoradiation. **Materials and Methods:** Histopathologically proven CaCx patients (n=50) and age-matched healthy females (n=50) were recruited in case-control study. Estimation of Serum TAC, and MDA was done in recruited subjects. Both of these parameters was estimated again after chemoradiation in CaCx patients, to scrutinize the effect of chemoradiation. In addition, 84% controls and 34% cervical cancer patients had a history of Vit. C and E supplementation. **Results:** The mean \pm SD age of the patients and controls was 43.98 \pm 6.38 and 31.56 \pm 6.84 years, respectively. The mean level of serum MDA in the patients was significantly higher as compared with the controls, whereas the mean TAC in the patients was reduced in same comparison. After chemoradiation, serum levels of TAC and MDA, increased and decreased, respectively. **Conclusion:** These analytical data captured suggests that patients with CaCx were in oxidative stress because the chosen oxidative parameters, serum MDA were increased, and the defensive TAC was decreased in them. Chemoradiotherapy improved their antioxidant capacity. Further studies are needed to evaluate the concurrent use of antioxidants with chemoradiotherapy for improving the disease prognosis.

Keywords: TAC, MDA, Cervical cancer, oxidative stress.

Copyright © 2021 The Author(s): This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY-NC 4.0) which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited.

INTRODUCTION

The third most frequently found cancer among females across the globe is cervical cancer (CaCx). In year 2012, it attributed for 266,000 deaths, 87% of this occurred in under developed nations, with maximum burden being in India [1, 2]. CaCx is a prominent cause of cancer related deaths in India, contributing 17% of deaths due to cancer in women aged in 3rd to 6th decade of life and second commonest cancer [3]. As far as current incidence rates considered, an increase to 225,000 is anticipated by 2025 in India [4,5] with just 42% chances of surviving [6]. The infection with sexually transmitted HPV is accepted as a dominant causal factor for developing CxCa[7]. HPV 16 & 18 being frequent association. Normally, host immunity bugs off majority of the viral infections, those which persist cause cancer in due course of time. Males being carrier of HPV in most cases, infecting and generating the disease in women. Majority of adults are unaware of

HPV infection and risks associated with it [7]. In absence of an effective treatment, its prevention still depends on cervical screening HPV and vaccination[8]. The open reading frames ORFs of HPV genome, like E1, E2, E4-E7 are involved in replication and oncogenesis by damaging DNA[9]. However, as per data role of oxidative stress in its development has been disclosed[10]. Generation of free radicals with a decrease in the levels of antioxidants, causes DNA damage, and mutation of tumor suppressor genes, thereby commencing and promoting multi-step carcinogenesis[11]. MDA is toxic outcome of peroxidation of poly unsaturated fatty acid, and is mutagenic to DNA at guanine site. This product of peroxidation of lipids can possibly lead to progression of uterine cancer [12,13]. Therefore the present study was done to assess the oxidative stress in cervical cancer patients in terms of TAC and MDA. And, to see the effect of chemoradiation on these.

MATERIALS AND METHODS

A prospective case-control study conducted among diagnosed cases of CaCx (n=50) and age matched healthy females (n=50) willing to participate in the study. Subjects with any chronic disease like cardio-vascular, respiratory, psychiatric, renal, neurological diseases and those with history of vitamin, mineral supplement, cigarette smoking, and alcohol intake were not recruited for the study. 3mL of blood collected from recruited subjects after an informed consent was centrifuged at 3000rpm for 10 minutes. Separated serum was stored at -40°C till the time of

analysis. In addition, blood from patients was drawn after chemoradiation as well for estimation of TAC and MDA. Five cycles of Cisplatin in a weekly dose of 40g/m² was given as chemotherapy, while four fractions of 7Gy each brachytherapy constituted radiotherapy. Two applications of radiotherapy were given one week apart.

The TAC and MDA in the collected serum was estimated by using ferric reducing ability of plasma (FRAP) assay by Benzie & Strain, 1996 [15] and Satoh K method respectively [16].




Fig-1: Workflow Chart

STATISTICAL ANALYSIS

Descriptive and inferential statistical analysis has been carried out in the present study. The Statistical software namely SAS 9.2, SPSS 15.0, Stata 10.1, MedCalc9.0.1, Systat 12.0 and R environment ver.2.11.1 were used for the analysis of the data and Microsoft word and graphs and tables were generated on Excel. Student t test (two tailed, independent) has been used to find the significance of study parameters. Chi-square test was used to find the significance of study parameters. Pearson correlation between serums MDA & TAC was performed to find the degree of relationship.

RESULTS

The study subjects, 50 from each group chosen after exclusion-inclusion criteria were recruited for the study. The mean age in Ca Cx patients was 43.98±6.38

yrs and in controls, it was 31.56±6.84. Among the cases, 50% were in the fourth to fifth decade of life (Fig.2). The mean serum TAC in the CaCx group was 781.36±228.88 μmol/L and in control group was 1088.94±185.07 μmol/L (Table 1) with 74% of cases and just 6% controls having values less than 875 μmol/L. The TAC in 90% healthy subject and 26% of diseased was between 875 and 1345 μmol/L, while as none of the patients and 4% of controls had value >1345 μmol/L (Table 2). The mean value of MDA in the CaCx and control group was 2.72±1.01 nmol/mL and 1.17±0.52 nmol/mL, respectively (Table 1), with 74% cases and only 8% of controls having >2.00 nmol/ml. The difference in both the parameters across groups was significant (p<0.001). A statistically significant negative correlation was found between Sr. TAC and MDA (r= -0.278, p= 0.050) in cervical cancer patients, while it was insignificant in healthy controls (Table 3). A statistically significant increase in Sr TAC

($p= 0.018$) and a decrease in Sr MDA ($p< 0.001$) was observed after chemoradiation in cervical cancer patients (Table 4). In addition, 84% controls and 34%

cervical cancer patients had a history of Vit. C and E supplementation. But the levels were not measured.




Fig-2: Bar diagram showing age distribution in study group




Fig-3: Bar diagram showing Sr. TAC in study groups




Fig-4: Bar diagram showing MDA levels in study groups.

Table-1: Mean comparison of study variables in cases and controls studied

Serum	Cases	Controls	P value
Total Antioxidant Capacity	781.36±228.88	1088.94±185.07	<0.001
Malondialdehyde	2.72±1.01	1.17±0.52	<0.001

p<0.001= statistically significant

Table-2: Comparison of Serum TAC and MDA in two groups studied.

Variables	Cases (n=50)		Controls (n=50)		P value
	No	%	No	%	
Total Antioxidant Capacity (µmol/L)					
<875	37	74.0	3	6.0	<0.001
875-1345	13	26.0	45	90.0	
>1345	0	0.0	2	4.0	
Malondialdehyde (nmol/ml)					
<1.05	2	4.0	21	42.0	<0.001**
1.05-2.00	11	22.0	25	50.0	
>2.00	37	74.0	4	8.0	

p<0.001= statistically significant

Table-3: Pearson correlation of Serum TAC with MDA

	Cases		Controls	
	r value	P value	r value	P value
Total Antioxidant Capacity vs Malondialdehyde	-0.278	0.050	0.158	0.272

Table-4: Comparison of TAC and MDA in cervical cancer patients before and after chemoradiation

	Cervical cancer		p-value
	Before CT	After CT	
Total Antioxidant Capacity (µmol/L)	781.36±228.88	917±358	0.018
Malondialdehyde(nmol/mL)	2.72±1.01	2.5±0.92	<0.001

p<0.001= statistically significant

DISCUSSION

Cervical cancer is the leading cause of cancer mortality in India, accounting for 17% of all cancer deaths among women in third to sixth decade of life [17]. The 5-year survival rate in <50years of age is 76%, and 72.5% had squamous cell carcinoma [18]. The associated morbidity, mortality and the cost to society due to CxCa, has made it important public healthcare challenge. The objective of identifying risk factors, early diagnosis and treatment is to reduce the associated morbidity and mortality. Oxidative stress as a causal factor in cervical cancer has been explored extensively. The mutations and unrestricted multiplication of cells through a series of events lead to the development of cancer. Recent published data set up oxidative stress and its associated damage contributing towards initiation and progression of cancer and its link with signalling of oncogenes [19, 20]. This study was designed to quantitate and compare serum TAC and MDA in diagnosed cases of cervical cancer and normal healthy females. And to assess the effect of treatment in the form of chemoradiation on these parameters in cancer patients. These two parameters were chosen to evaluate the oxidative stress in cervical patients. Role of oxidative stress using different parameters in different

cancers in different stages has been extensively studied in recent times.

One of the final and harmful products of lipid peroxidation is MDA, which has been used as a biomarker in many platforms to estimate the depth of oxidative stress and cell damage by its ability to bind to the proteins at free amino groups, nucleic acids [21, 22]. The quantitated levels of MDA in our study was significantly higher (p<0.001) in CaCx serum compared to the normal one. Similar increased levels of circulating MDA was found by Grace *et al.*, to assess the extent of lipid peroxidation [23]. This was attributed to accelerated lipid peroxidation parallel to compromised defensive antioxidant mechanism in CaCx patients. As per Naidu *et al.* the elevated serum MDA levels in their patients was a possible cause of progression of CaCx.[10] With the similar results, Demirci *et al.* explained that an increased MDA levels and DNA damage maybe a result of oxidative damage, which further leads to mutagenesis, cell death and carcinogenesis. [24]. Similarly, a raised MDA in CIN cases as compared to control group has been reported [25, 26].

The intermediary product of different metabolic processes in subcellular organelles along with other processes like oxidation of fatty acids are reactive oxygen species (ROS), which are secreted in minute quantity of picomoles. The unrestricted amounts are taken care of by the antioxidant present. Imbalance in this system leads to increase in ROS, thereby causing chronic diseases like cancer, diabetes mellitus etc. increased free radicals results in malignancy and metastasis [27, 28]. Both the bigger molecules like catalase, SOD etc and the smaller ones like carotenoids, vit. C and E have a capacity to control the redox balance in malignant cells. Diseases can be prevented by dietary antioxidants [29]. Therefore, the relationship between a decreased antioxidant level and malignancy and premalignant conditions has been evaluated by researchers at various strata. The defensive antioxidant system in human bodies depends upon the intake in diet and endogenous formation [28].

The TAC measures the antioxidant potential of all the antioxidants in the serum, so we chose TAC estimation in our study. It was found to be decreased ($p < 0.001$) in patients as compared to controls like that of Demirici *et al.*, and Rong *et al.*, [24,30]. In addition, Kim *et al.* and Lee *et al.*, associated the lower levels of TAC in CIN patients as compared to that of healthy females [25, 26].

One more finding of our study was opposite drift in Serum TAC and MDA in patients of cervical cancer post chemoradiation in comparison to pre-treatment levels. Standard cancer treatment by radiotherapy exerts its effect by generating local oxidative stress leading to damaging the cellular proteins, DNA, lipids and governs an abnormal cell signalling, this results in cancer cell death [31]. As per Sun L *et al.* the total antioxidant capacity of whole blood decreases in proportion to the doses of irradiation given [32].

CONCLUSION

Our study demonstrated dysregulated levels of serum TAC and MDA levels in cervical cancer compared to healthy females. An imbalance in these parameters sets in oxidative stress and may play a role in initiation and progression of cancer. Further, the balance of oxidant-antioxidant system shifts towards the improvement in the antioxidant status after chemoradiation. Many more studies at various platforms in a larger cohort of cases extended over longer time are required to evaluate effects of antioxidant supplements on cancer initiation and metastasis.

Limitations

The sample size and the time period taken was small and results cannot be used as a conclusive evidence if concurrent antioxidant supplements can improve outcome after chemoradiation.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

ACKNOWLEDGMENT

We are thankful to the patients who despite being in pain and distress gave their consent to conduct this study. We acknowledge Mr. Furqan Amin Khan and Mr. Haris M Shah for designing the graphics which were used in the manuscript.

REFERENCES

1. Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., & Bray, F. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *International journal of cancer*, 136(5), E359-E386.
2. Campos, N. G., Tsu, V., Jeronimo, J., Regan, C., Resch, S., Clark, A., & Kim, J. J. (2019). Health impact of delayed implementation of cervical cancer screening programs in India: A modeling analysis. *International journal of cancer*, 144(4), 687-696.
3. Kumar, D., Dey, T., Bansal, P., Srinivasa, G. Y., & Rai, B. (2020). Sociodemographic and clinical profile of geriatric patients with cervical cancer—An audit from a tertiary cancer center in India. *Journal of Family Medicine and Primary Care*, 9(3), 1528.
4. Sreedevi, A., Javed, R., & Dinesh, A. (2015). Epidemiology of cervical cancer with special focus on India. *International journal of women's health*, 7, 405.
5. Krishnan, S., Madsen, E., Porterfield, D., & Varghese, B. (2013). Advancing cervical cancer prevention in India: implementation science priorities. *The oncologist*, 18(12), 1285.
6. Catarino, R., Petignat, P., Dongui, G., & Vassilakos, P. (2015). Cervical cancer screening in developing countries at a crossroad: Emerging technologies and policy choices. *World journal of clinical oncology*, 6(6), 281.
7. Braaten, K. P., & Laufer, M. R. (2008). Human papillomavirus (HPV), HPV-related disease, and the HPV vaccine. *Reviews in obstetrics and gynecology*, 1(1), 2.
8. Hu, Z., & Ma, D. (2018). The precision prevention and therapy of HPV- related cervical cancer: new concepts and clinical implications. *Cancer medicine*, 7(10), 5217-5236.
9. Burd, E. M. (2003). Human papillomavirus and cervical cancer. *Clinical microbiology reviews*, 16(1), 1-17.
10. Naidu, M. S. K., Suryakar, A. N., Swami, S. C., Katkam, R. V., & Kumbar, K. M. (2007). Oxidative stress and antioxidant status in cervical

- cancer patients. *Indian Journal of Clinical Biochemistry*, 22(2), 140-144.
11. Georgescu, S. R., Mitran, C. I., Mitran, M. I., Caruntu, C., Sarbu, M. I., Matei, C., ... & Popa, M. I. (2018). New insights in the pathogenesis of HPV infection and the associated carcinogenic processes: the role of chronic inflammation and oxidative stress. *Journal of immunology research*, 2018.
 12. Barrera, G. (2012). Oxidative stress and lipid peroxidation products in cancer progression and therapy. *International Scholarly Research Notices*, 2012.
 13. Jelić, M., Mandić, A., Kladar, N., Sudji, J., Božin, B., & Srdjenović, B. (2018). Lipid peroxidation, antioxidative defense and level of 8-hydroxy-2-deoxyguanosine in cervical cancer patients. *Journal of medical biochemistry*, 37(3), 336-345.
 14. Cervellati, C., Romani, A., Seripa, D., Cremonini, E., Bosi, C., Magon, S., ... & Zuliani, G. (2014). Systemic oxidative stress and conversion to dementia of elderly patients with mild cognitive impairment. *BioMed research international*, 2014.
 15. Benzie, I. F., & Strain, J. J. (1996). The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. *Analytical biochemistry*, 239(1), 70-76.
 16. Sotoh, K. (1978). Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. *Clin Chim Acta*, 90, 37-43.
 17. Bobdey, S., Sathwara, J., Jain, A., & Balasubramaniam, G. (2016). Burden of cervical cancer and role of screening in India. *Indian journal of medical and paediatric oncology: official journal of Indian Society of Medical & Paediatric Oncology*, 37(4), 278.
 18. Balasubramaniam, G., Gaidhani, R. H., Khan, A., Saoba, S., Mahantshetty, U., & Maheshwari, A. Survival rate of cervical cancer from a study conducted in India. *Indian Journal of Medical Sciences*, 1-10.
 19. Klaunig, J.E. (2018). Oxidative stress and cancer. *Curr pharm des. Nov 1;24(40):4771-8*.
 20. Gill, J. G., Piskounova, E., & Morrison, S. J. (2016, January). Cancer, oxidative stress, and metastasis. In *Cold Spring Harbor symposia on quantitative biology* (Vol. 81, pp. 163-175). Cold Spring Harbor Laboratory Press.
 21. Macotpet, A., Suksawat, F., Sukon, P., Pimpakdee, K., Pattarapanwichien, E., Tangrassameeprasert, R., & Boonsiri, P. (2013). Oxidative stress in cancer-bearing dogs assessed by measuring serum malondialdehyde. *BMC veterinary research*, 9(1), 1-6.
 22. Rašić, I., Rašić, A., Akšamija, G., & Radović, S. (2018). The relationship between serum level of malondialdehyde and progression of colorectal cancer. *Acta Clinica Croatica*, 57(3.), 411-416.
 23. Nirmala, J. G., & Narendhirakannan, R. T. (2011). Detection and genotyping of high-risk HPV and evaluation of anti-oxidant status in cervical carcinoma patients in Tamil Nadu State, India—a case control study. *Asian Pacific Journal of Cancer Prevention*, 12(10), 2689-2695.
 24. Demirci, S., Ozsaran, Z., Celik, H. A., Aras, A. B., & Aydin, H. H. (2011). The interaction between antioxidant status and cervical cancer: a case control study. *Tumori Journal*, 97(3), 290-295.
 25. Kim, J. W., Choi, E. K., Lim, J. H., Kim, Y. T., Kim, D. K., Lee, Y. C., ... & Chung, H. Y. (2002). Antioxidant system and oxidative stress in uterine cervical neoplasia of Korean women. *Korean Journal of Obstetrics and Gynecology*, 45(1), 145-152.
 26. Lee, G. J., Chung, H. W., Lee, K. H., & Ahn, H. S. (2005). Antioxidant vitamins and lipid peroxidation in patients with cervical intraepithelial neoplasia. *Journal of Korean medical science*, 20(2), 267.
 27. George, S., & Abrahamse, H. (2020). Redox Potential of Antioxidants in Cancer Progression and Prevention. *Antioxidants*, 9(11), 1156.
 28. Kurutas, E. B. (2015). The importance of antioxidants which play the role in cellular response against oxidative/nitrosative stress: current state. *Nutrition journal*, 15(1), 1-22.
 29. Nimse SB, Pal D. Free radicals, natural antioxidants, and their reaction mechanisms. *RSC advances*. 2015;5(35):27986-8006.
 30. Wu, R., Feng, J., Yang, Y., Dai, C., Lu, A., Li, J., ... & Du, X. B. (2017). Significance of serum total oxidant/antioxidant status in patients with colorectal cancer. *PLoS One*, 12(1), e0170003.
 31. Serbanescu, G. L., Gruia, M. I., Bara, M., & Anghel, R. M. (2017). The evaluation of the oxidative stress for patients receiving neoadjuvant chemoradiotherapy for locally advanced rectal cancer. *Journal of medicine and life*, 10(1), 99.
 32. Sun, L., Inaba, Y., Sato, K., Hirayama, A., Tsuboi, K., Okazaki, R., & Moritake, T. (2018). Dose-dependent decrease in anti-oxidant capacity of whole blood after irradiation: A novel potential marker for biodosimetry. *Scientific reports*, 8(1), 1-8.